Metabolic reprogramming in lung cancer and its clinical implication
Frontiers in Pharmacology · 18.12.2024 · 15
DOI: 10.3389/fphar.2024.1516650 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.12.2024. Verfasst von Qingqiu Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer has posed a significant challenge to global health, and related study has been a hot topic in oncology. This article focuses on metabolic reprogramming of lung cancer cells, a process to adapt to energy demands and biosynthetic needs, supporting the proliferation and development of tumor cells. In this study, the latest studies on lung cancer tumor metabolism were reviewed, including the impact of metabolic products and metabolic enzymes on the occurrence and development of lung cancer, as well as the progress in the field of lung cancer treatment targeting relevant metabolic pathways. This provides some promising potential directions into exploring lung cancer tumor metabolism and helps researchers to better understand lung cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Sichuan Province Revolutionary Disable Armyman Rehab, The First Veterans Hospital Of Sichuan Province, Chengdu, China.
- School of Pharmaceutical Sciences, Guizhou University, Guiyang, China.
- Department of Outpatient, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Zitieren
APA
Huang, Q., Fan, L., Gong, M., Ren, J., Chen, C., & Xie, S. (2024). Metabolic reprogramming in lung cancer and its clinical implication. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1516650
Vancouver
Huang Q, Fan L, Gong M, Ren J, Chen C, Xie S. Metabolic reprogramming in lung cancer and its clinical implication. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1516650
BibTeX
@article{Huang2024,
author = {Huang, Qingqiu and Fan, Lisha and Gong, Mingjing and Ren, Juntong and Chen, Chen and Xie, Shenglong},
title = {Metabolic reprogramming in lung cancer and its clinical implication},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1516650}
}
EUVIMED